
Published 06 May 2026
GLP‑1 medications are reshaping not just bodies, but minds, habits and desires. From ‘Ozempic personality’ to ‘emotional flattening’ and ‘refined pleasure centres’, today’s users are navigating a profound shift in how they experience emotion and everyday life. For brands, the opportunity to support this growing population – from offering thoughtfully designed wellbeing products to emotionally attuned lifestyle experiences – is enormous.
A new class of medication is rewriting the rules of obesity treatment – and with it, reshaping the health landscape on a scale never seen before. GLP-1 eligibility spans more than a quarter of the global adult population (Mass General Brigham, 2026), yet access remains unequal, divided by gender, age, wealth and geography. For earlier reading here, see The Blockbuster Weight Loss Boom.
A new class of medication is rewriting the rules of obesity treatment – and with it, reshaping the health landscape on a scale never seen before. GLP-1 eligibility spans more than a quarter of the global adult population (Mass General Brigham, 2026), yet access remains unequal, divided by gender, age, wealth and geography. For earlier reading here, see The Blockbuster Weight Loss Boom.
GLP‑1 medications are transformative for many users because meaningful weight loss often brings a surge in confidence, mobility, social comfort, and overall quality of life. Simultaneously, they can introduce emotional challenges, including heightened focus on body image, ‘emotional flattening’, and vulnerability to anxiety or depression, especially for those with a history of mental health conditions or complex relationships with food and weight.
GLP‑1 users are eating less, but they’re also eating with purpose. They’re building meals around foods that support energy, satisfaction and long‑term wellbeing – with muscle-preserving protein and digestion-supporting fibre becoming central anchors of daily nourishment. Early research and reporting also suggest that some users may naturally reduce their alcohol intake, shifting social habits and opening space for new sober-curious rituals.



Offering access to over 350 consumer and cross-industry reports annually, Stylus Membership is your window to tomorrow’s most exciting opportunities.
We already arm more than 500 of the world’s most forward-thinking brands and agencies with the creative insights they need to make transformative business decisions.
We’d love to do the same for you.
Book a demo with us today to discover more.
GLP‑1 medications are reshaping not just bodies, but minds, habits and desires. From ‘Ozempic personality’ to ‘emotional flattening’ and ‘refined pleasure centres’, today’s users are navigating a profound shift in how they experience emotion and everyday life. For brands, the opportunity to support this growing...